Literature DB >> 6242478

An oriented phase-II trial of D-Trp6-LH-RH in patients with prostatic carcinoma.

G Mathé, M L Vo Van, J Duchier, J L Misset, P Morin, R Keiling, L Schwarzenberg, P Kerbrat, E Achille, J C Tronc.   

Abstract

An oriented phase II trial of D-Trp6-LH-RH was conducted according to Gehan's statistical method on 25 patients suffering from prostatic carcinoma. LH and testosterone serum levels decreased rapidly. Pain disappeared during the third month in 14 out of the 21 patients and markedly decreased in 5. Prostatism completely regressed in 10 out of the 22 subjects presenting it and markedly decreased in 9. Prostate hypertrophy regressed, as shown by ultrasonography, in 84% and by more than 50% in 37% of the patients. The overall regression rate of bone scintigraphy images was 43%; a regression of more than 50% was only registered in 12.5% of the patients; this may be explained by the long time which is necessary before bone image disappearance occurs. Prostatic acid phosphatase levels regressed in 75% and by more than 50% in 66.7% of the patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6242478     DOI: 10.1007/bf02934983

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  11 in total

1.  Gonadotropin secretion in eugonadotropic human males and postmenopausal females under long-term application of a potent analog of gonadotropin-releasing hormone.

Authors:  J Happ; P Scholz; T Weber; U Cordes; P Schramm; M Neubauer; J Beyer
Journal:  Fertil Steril       Date:  1978-12       Impact factor: 7.329

2.  [Phase II comparative trials for confirmation of the null hypothesis. Their interest, particularly in oncology].

Authors:  J L Misset; H Gaget; G Mathé
Journal:  Biomed Pharmacother       Date:  1983       Impact factor: 6.529

3.  Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive.

Authors:  R Linde; G C Doelle; N Alexander; F Kirchner; W Vale; J Rivier; D Rabin
Journal:  N Engl J Med       Date:  1981-09-17       Impact factor: 91.245

Review 4.  Recent approaches to fertility control based on derivative of LH-RH.

Authors:  A V Schally; A Arimura; D H Coy
Journal:  Vitam Horm       Date:  1980       Impact factor: 3.421

5.  Statistical contributions to phase II trials in cancer: interpretation, analysis and design.

Authors:  Y J Lee; R A Wesley
Journal:  Semin Oncol       Date:  1981-12       Impact factor: 4.929

6.  Treatment and survival of patients with cancer of the prostate. The Veterans Administration Co-operative Urological Research Group.

Authors: 
Journal:  Surg Gynecol Obstet       Date:  1967-05

Review 7.  LH-RH agonists and antagonists.

Authors:  A V Schally; D H Coy; A Arimura
Journal:  Int J Gynaecol Obstet       Date:  1980       Impact factor: 3.561

8.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

9.  Inhibition of the growth of some hormone dependent tumors by D-Trp6-LH-RH.

Authors:  A V Schally; T W Redding; A M Comaru-Schally
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

10.  Advanced prostatic adenocarcinoma: biological aspects and effects of androgen deprivation achieved by castration or agonistic analogues of LHRH.

Authors:  G Tolis; M Koutsilieris; R Herrera; A Stellos; A Martinez; M Dufresne
Journal:  Med Oncol Tumor Pharmacother       Date:  1984
View more
  2 in total

1.  Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model.

Authors:  A V Schally; T W Redding
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

2.  Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.

Authors:  A V Schally; A I Kook; E Monje; T W Redding; J I Paz-Bouza
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.